01.20.16
Allan L. Shaw Joins Syndax Pharmaceuticals as Chief Financial Officer
Read More
01.04.16
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer
Read More
12.03.15
Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium
Read More
12.01.15
Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin
SYNDAX ANNOUNCES INITIATION OF ENTINOSTAT CLINICAL PROGRAM IN JAPAN BY PARTNER KYOWA HAKKO KIRIN
Read More
09.28.15
Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And Keytruda®
Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And Keytruda ®
Read More
09.16.15
Syndax to Present at Two Upcoming Scientific Conferences
Read More
09.01.15
Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals as SVP and Chief Development Officer
Read More
08.26.15
Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
Read More
08.24.15
Syndax Raises $80 Million in Series C Financing
Read More
06.15.15
Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer
Read More
03.31.15
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA ® (pembrolizumab) in Lung Cancer and Melanoma
Read More
03.12.15
Syndax to Participate in Two Upcoming Conferences
Read More